Showing results (1541-1550 of 1,553) with videos related to

Sort By:
Pageof 156
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
European Urology Oncology|January 13, 2021
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium StudyQuesta Karlsson, Mark N Brook, Tokhir Dadaev, et al.
Cancer Letters|March 12, 2016
CGCG clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Ying Mao, Wenbin Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
Frontiers in Oncology|October 12, 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung AdenocarcinomaLong-Hua Guo, Ming-Feng Zhang, He-Long Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Zhijie Wang, Lin Wu, Baolan Li, et al.
Cancer Letters|November 9, 2020
Clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Do-Hyun Nam, Zvi Ram, et al.
Cancer Cell|September 10, 2024
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancerJiachen Xu, Rui Wan, Yiran Cai, et al.
Cancer Letters|December 3, 2025
Updated clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Do-Hyun Nam, Zvi Ram, et al.
Signal Transduction and Targeted Therapy|December 23, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trialJia Zhong, Kailun Fei, Lin Wu, et al.
Pageof 156